Evaluating comparative effectiveness of psychosocial interventions for persons receiving opioid agonist therapy for opioid use disorder: protocol for a systematic review. Issue 10 (18th October 2018)

• Record Type: Journal Article
• Authors: Rice, Danielle B; Hutton, Brian; Poulin, Patricia; Sproule, Beth A; Wolfe, Dianna; Moher, David; Thavorn, Kednapa; Garber, Gary; Taha, Sheena; Porath, Amy; Willows, Melanie; Esmaeilisaraji, Leila; Yazdi, Fatemeh; Shea, Beverley; Skidmore, Becky; Corace, Kimberly
• Is Part Of: BMJ open. Volume 8:Issue 10(2018)
• Publication Date: 2018-10-18
• Subjects: opioid use disorder -- systematic review -- psychosocial interventions -- pharmacological interventions -- addiction medicine -- network meta-analysis; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2018-023902
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Introduction: The opioid crisis has resulted in increasing rates of death caused by problematic opioid use. Current clinical guidelines recommend that individuals with persons with opioid use disorder (OUD) receive pharmacological (eg, opioid agonist therapy) and psychosocial (eg, cognitive behavioural therapy) therapy; however, the best combination of pharmacologic and psychosocial components is not known. Our objective of the planned study is to conduct a comprehensive systematic review to assess the relative benefits of psychosocial interventions as an adjunct to opioid agonist therapy among persons with OUD. Methods and analysis: A comprehensive search for randomised controlled trials published in English or French will be conducted from database inception to March 2018. The search will be conducted in MEDLINE and translated for Embase, PsycINFO and the Cochrane Central Register of Controlled Trials. Two independent reviewers will screen, extract and assess risk of bias of eligible articles. Primary outcomes of interest will be treatment retention and opioid use (based on urinalysis results). Secondary outcomes will include self-reported opioid use, abstinence from illicit drugs, adherence to psychosocial therapy and opioid agonist therapy, risk for sexually transmitted disease, risk for blood borne pathogens, changes in mental health symptoms (eg, depression), measures of craving and changes in patients' quality of life and relevant adverse events. If sufficient data and adequate homogeneity exists, network meta-analyses (NMA) will be performed. Ethics and dissemination: This will be the first systematic review to incorporate NMA to compare psychosocial treatments used as an adjunct to opioid agonist therapy for OUD. Results of this review will inform clinical management of persons with OUD. Trial registration number: CRD42018090761.